|
|
 |
 |
| |
 Printable version |
A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma |
Bulletin du Cancer. Volume 93, Number 11, 10115-8, Novembre 2006, Electronic Journal of Oncology
|
 Free Article
|
Author(s) : Charles Dumontet, Luc Thomas, Frédéric Bérard, Jean François Gimonet, Bertrand Coiffier |
Summary : A phase II trial evaluating 6% topical miltefosine solution was performed in 12 pretreated patients with cutaneous T-cell lymphoma. Miltefosine (Miltex
®) was administered for 8 weeks, once per day during the first week then twice every day for seven weeks. Main side effects consisted in moderate to mild pruritus or desquamation in 57 % and 50 % of patients, respectively. No systemic nor biological toxicity was observed. This treatment was administered on an outpatient basis exclusively. The overall response rate was 58 % with a median duration of response of 12 months. Miltefosine is a safe, simple and effective treatment in certain patients with cutaneous T-cell lymphoma. |
Keywords : miltefosine, cutaneous T-cell lymphoma |
|
